CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma.
Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS)是接受CAR-T 细胞(CAR-T 细胞)治疗的复发/难治性弥漫性大B细胞淋巴瘤患者的重要并发症。
然而,CAR-T 细胞表达本身是否具有临床相关性仍不清楚。我们通过微滴数字PCR评估了14例连续CAR-T 细胞接受者外周血中的CAR-T 细胞mRNA表达和DNA浓度。根据CAR-T 细胞峰值表达对患者进行分组。CAR-T 细胞峰值表达高的患者(8例;57%)ICANS发生率(p=0.0308)和重症监护室入住率(p=0.0404)更高,住院时间更长(p=0.0077),并且尽管无统计学显著性,CRS发生率也更高(p=0.0778)。CAR-T 细胞mRNA表达与DNA浓度存在相关性,但CAR-T 细胞表达水平与缓解或生存无关。
我们的数据提示,较高的CAR-T 细胞峰值mRNA表达与ICANS风险增加相关,并可能与CRS相关,需要在更大规模的研究中进一步探讨。CAR-T 细胞峰值表达较高的患者(8 例;57%)具有更高的 ICANS(p=0.0308)和重症监护室入住率(p=0.0404)、更长的住院时间(p=0.0077),以及尽管无统计学显著性但更高的 CRS 发生率(p=0.0778)。CAR-T 细胞 mRNA 表达与 DNA 浓度之间存在相关性,但 CAR-T 细胞表达水平与缓解或生存无相关性。
我们的数据表明,较高的 CAR-T 细胞峰值 mRNA 表达与增加的 ICANS 以及可能的 CRS 风险相关,这需要在更大规模的研究中进一步探讨。
Cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are significant complications in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing chimeric antigen receptor T-cell (CAR-T cell) therapy.
However, it remains unclear whether CAR-T cell expression itself is clinically relevant.
We assessed CAR-T cell mRNA expression and DNA concentration by digital droplet PCR in peripheral blood from 14 sequential CAR-T cell recipients. Patients were grouped according to CAR-T cell peak expression. Patients with high CAR-T cell peak expression (8 patients; 57%) had higher rates of ICANS (p=0.
0308) and intensive care unit admission (p=0. 0404), longer durations of hospitalization (p=0. 0077), and, although not statistically significant, a higher rate of CRS (p=0. 0778). There was a correlation of CAR-T cell mRNA expression with DNA concentration, but CAR-T cell expression levels failed to correlate to response or survival.
Our data suggest that higher CAR-T cell peak mRNA expression is associated with increased risk for ICANS and possibly CRS, requiring further investigation in larger studies. Sitokin sal m sendromu (CRS) ve imm n efekt r h cre ile ili kili n rotoksisite sendromu (ICANS), kimerik antijen resept r T-h cresi (CAR-T h cresi) tedavisi g ren n ksetmi /refrakter diff z b y k B-h creli lenfoma hastalar nda nemli komplikasyonlard r. Bununla birlikte, CAR-T h cre ifadesinin klinikle ili kili olup olmad belirsizli ini korumaktad r. Ond rt CAR-T h cre al c s ndan periferik kanda dijital damlac k PCR ile CAR-T h cresi mRNA ekspresyonunu ve DNA konsantrasyonunu de erlendirdik.
Hastalar, CAR-T h cre pik ifadesine g re grupland r ld . Y ksek CAR-T h cre pik ekspresyonu olan hastalar (8 hasta; %57) daha y ksek ICANS (p=0,0308) ve yo un bak ma yat (p=0,0404), daha uzun hastanede yat s releri (p=0,0077) ve istatistiksel olarak anlaml olmasa da, daha y ksek CRS oran na sahipti (p=0,0778).
CAR-T h cresi mRNA ekspresyonu ile DNA konsantrasyonu aras nda bir korelasyon vard , ancak CAR-T h cresi ekspresyon seviyeleri, yan t veya hayatta kalma ile korelasyon g stermedi. Verilerimiz, daha y ksek CAR-T h cre zirvesi mRNA ekspresyonunun, daha b y k al malarda daha fazla ara t rmay gerektiren, artan ICANS ve muhtemelen CRS riski ile ili kili oldu unu g stermektedir.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。